ライフサイエンスコーパス: praziquantel

1 primarily by mass administration of the drug praziquantel.

2 facturers, and the reduced price of the drug praziquantel.

3 histosoma mansoni and HIV-1 was treated with praziquantel.

4 incipally the safe and relatively cheap drug praziquantel.

5 d patients was followed by chemotherapy with praziquantel.

6 stosomiasis relies on mass administration of praziquantel.

7 by surgical excision followed by a course of Praziquantel.

8 but its treatment relies on a single agent, praziquantel.

9 d with an oral standard single-dose 40 mg/kg praziquantel.

10 mass treatment with the only available drug, praziquantel.

11 received between 1 and 9 rounds of MDA with praziquantel.

12 s before and 25-27 days after treatment with praziquantel.

13 s predominantly on the use of a single drug, praziquantel.

14 d mice treated with the antischistosome drug praziquantel.

15 atment of schistosomiasis relies on the drug praziquantel.

16 aths annually, depends almost exclusively on praziquantel.

17 azole (odds ratio 0.70, 95% CI 0.35-1.42) or praziquantel (0.60, 0.29-1.23) treatment.

18 All group 1 patients were treated with praziquantel; 1 patient with myeloradiculopathy also rec

19 praziquantel, 13.6% (11.6-14.6) for two-dose praziquantel, 11.8% (9.4-13.4) for novel drug A, 12.6% (

20 alence was 14.6% (12.2-16.4) for single-dose praziquantel, 13.6% (11.6-14.6) for two-dose praziquante

21 ertainty interval 15.8-23.6) for single-dose praziquantel, 17.8% (15.2-19.8) for two-dose praziquante

22 praziquantel, 17.8% (15.2-19.8) for two-dose praziquantel, 18.4% (13.4-21.4) for novel drug A, 16.0%

23 se praziquantel, 2.8% (2.2-3.4) for two-dose praziquantel, 2.6% (1.8-3.2) for novel drug A, 2.7% (2.2

24 revalence was 3.0% (2.2-3.6) for single-dose praziquantel, 2.8% (2.2-3.4) for two-dose praziquantel,

25 treatment was 4.8% (3.6-5.8) for single-dose praziquantel, 4.2% (3.6-5.0) for two-dose praziquantel,

26 se praziquantel, 4.2% (3.6-5.0) for two-dose praziquantel, 4.6% (3.2-5.4) for novel drug A, 4.0% (3.4

27 54 children were randomly assigned to either praziquantel 40 mg/kg at baseline and placebo at 6 month

28 Praziquantel 40 mg/kg was administered to the patient.

29 e assessed a 5-year treatment programme with praziquantel (40 mg/kg per treatment) against schistosom

30 ing system, represented by the antihelmintic praziquantel, 8.

31 rs of gene families previously implicated in praziquantel action, but detect no high frequency functi

32 Praziquantel, administered at a single 40 mg/kg dose in

33 Intensive praziquantel administration also reduced week 8 HPV-16-s

34 We show evidence suggesting that praziquantel administration improves the BCG-specific ce

35 Four hours sampling time-point post-praziquantel administration is ideal optimal single samp

36 s of S mansoni status at baseline) intensive praziquantel administration significantly improved week

37 d 164 [69%] in the standard group) intensive praziquantel administration significantly reduced pre-va

38 were collected at 0, 1, 2, 4, 6 and 8 h post-praziquantel administration.

39 ld be reversed-at least in part-by intensive praziquantel administration.

40 ere given one dose of approximately 40 mg/kg praziquantel after the week 8 primary endpoint.

41 mes; novel drug B, with higher efficacy than praziquantel against adult schistosomes and no activity

42 s: novel drug A, with equivalent efficacy to praziquantel against adult schistosomes plus perfect (10

43 and novel drug C, with higher efficacy than praziquantel against adult schistosomes plus perfect eff

44 emonstrated a direct preventive potential of Praziquantel against the onset of fibrosis and the confi

45 al trials with pairwise comparison of drugs (praziquantel, albendazole, mebendazole, tribendimidine,

46 ne of three interventions: biannual MDA with praziquantel alone (arm 1) or in combination with snail

47 85.7-97.5]), while a single dose of 50 mg/kg praziquantel also resulted in a high predicted cure rate

48 aneous treatment of coinfected children with praziquantel and albendazole affected schistosome- and h

49 d disability averted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and so

50 WHO guidelines to integrated treatment (both praziquantel and albendazole).

51 ziquantel-matching placebo (n=625), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626)

52 Both total praziquantel and its enantiomers (R- and S-praziquantel)

53 Quantification of praziquantel and its enantiomers (R- and S-praziquantel)

54 The search for alternatives to praziquantel and other tools for control of schistosomia

55 ew strategies for potentiating the action of praziquantel and possibly overcoming drug resistance.

56 be six times higher than WHO guidelines for praziquantel and two times higher for albendazole.

57 elated immune responses after treatment with praziquantel and whether the development of these immune

58 Administration of anthelmintic (praziquantel) and antioxidant (N-acetylcysteine plus def

59 ected individuals 1 month posttreatment with praziquantel, and antibody responses were measured using

60 Millions of people are treated annually with praziquantel, and drug-resistant parasites thus are like

61 tively with albendazole and selectively with praziquantel, and monitored for 6 months.

62 Sj67, measured 4 weeks after treatment with Praziquantel, and resistance to reinfection in a populat

63 of the neglected disease Schistosomiasis is Praziquantel, and the possible emergence of resistance m

64 ther empiric albendazole every 3 months plus praziquantel annually (treatment group) or to standard c

65 Single-dose praziquantel appears to be as efficacious as the standar

66 increase in viral load after treatment with praziquantel are unclear, these results do not support t

67 apeutic potentials of the antiparasitic drug Praziquantel as a possible antifibrotic.

68 -30 years old, all of whom were treated with praziquantel at baseline.

69 albendazole) vs standard (annual single-dose praziquantel, biannual single-dose albendazole) anthelmi

70 -infection studies in humans have shown that praziquantel can have long-term effects beyond a transie

71 mass administration with a single chemical, praziquantel, carries the risk that drug resistance will

72 f praziquantel and its enantiomers (R- and S-praziquantel) concentrations was done by Liquid chromato

73 enile schistosomes with higher efficacy than praziquantel could have some public health gains in cont

74 Administration of the anthelmintic drug praziquantel decreases the risk of CCA from liver flukes

75 Treatment with praziquantel did not have a significant effect on birthw

76 es are more likely to be exposed not only to praziquantel directly but also to hosts with altered imm

77 l praziquantel and its enantiomers (R- and S-praziquantel) displayed a wide inter-individual pharmaco

78 ipants in the intensive group received three praziquantel doses (approximately 40 mg/kg) 2 weeks apar

79 addition, studies that address the safety of praziquantel during pregnancy could lead to further adop

80 had ERRs below the 90% threshold of optimal praziquantel efficacy set by the World Health Organizati

81 mansoni populations with documented reduced praziquantel efficacy.

82 r monitoring of a pharmacologically active R-praziquantel enantiomer.

83 me-point for therapeutic monitoring of total praziquantel exposure while 6 h sampling time-point is s

84 al single sampling time-point for monitoring praziquantel exposure.

85 andan children from regions with contrasting praziquantel exposure.

86 and after the large-scale administration of praziquantel for schistosomiasis and albendazole for soi

87 Optimal dosing of praziquantel for schistosomiasis for children younger th

88 unger ages through the forthcoming pediatric praziquantel formulation and improving treatment coverag

89 the development of an appropriate paediatric praziquantel formulation, and present blocks are identif

90 ion, the regimen of 50 mg/kg and 25 mg/kg of praziquantel given in a single day showed the highest pr

91 e reactions occurred in five patients in the praziquantel group and two in the placebo group, and inc

92 group (184 to the placebo group, 186 to the praziquantel group).

93 racemate to the desirable (R)-enantiomer of Praziquantel has been developed by coupling incompatible

94 Thus, praziquantel has remained the frontline treatment for sc

95 dependent on the continued high efficacy of praziquantel; however, drug efficacy is rarely monitored

96 The reduced efficacy of praziquantel in schools with a higher exposure to MDA ma

97 efforts to expand the use of cheap, generic, praziquantel in sub-Saharan Africa.

98 As mass drug administration with praziquantel increases in an attempt to transition from

99 flux measurements of a fluorescent analog of praziquantel indicate that it is also a substrate for SM

100 creased by multiple rounds of infections and praziquantel-induced cures.

101 Only praziquantel is available for treating schistosomiasis,

102 Until a paediatric formulation of praziquantel is available in endemic areas, the use of c

103 ministration (MDA) programmes using the drug praziquantel is resulting in substantial increases in th

104 ounting evidence showing that treatment with praziquantel is safe, beneficial, and could be delivered

105 Mass drug administration (MDA) with praziquantel is the cornerstone of schistosomiasis contr

106 Annual mass drug administration (MDA) using praziquantel is the cornerstone of schistosomiasis morbi

107 Praziquantel is the first-line treatment, and it is also

108 ailable: treatment of infected patients with praziquantel is the mainstay of control efforts.

109 No vaccine is available, and only one drug (praziquantel) is used against the parasite.

110 A single drug, praziquantel, is used to treat schistosome infection.

111 loyed to synthesize trans-dragmacidine C and praziquantel-like molecules.

112 tions to offer pregnant women treatment with praziquantel, many nations continue to withhold treatmen

113 aziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziqua

114 626), or an albendazole-matching placebo and praziquantel-matching placebo (n=628).

115 patients to 440 mg albendazole and 40 mg/kg praziquantel (n=628), 440 mg albendazole and a praziquan

116 tors and to calculate the number of doses of praziquantel needed for prevention of morbidity.

117 The numbers of doses of praziquantel needed per year were estimated to be 123 mi

118 chistosomiasis has demonstrated an impact of praziquantel on hemoglobin concentration.

119 ction with S. japonicum after treatment with praziquantel on the mean hemoglobin level, iron-deficien

120 0 mg/kg, 40 mg/kg, 50 mg/kg, or 3 x 25 mg/kg praziquantel or placebo.

121 esumptive treatment for schistosomiasis with praziquantel; peer education (PE), in which a nominated

122 Praziquantel pharmacokinetics studies in schistosomiasis

123 n any other sampling time-point; while for R-praziquantel, plasma concentrations collected at 6 h sam

124 dazole daily for 3 days) or standard (annual praziquantel plus 6 monthly single-dose albendazole) MDA

125 munity-wide intensive (quarterly single-dose praziquantel plus albendazole daily for 3 days) or stand

126 chistosomiasis has relied on a single drug - praziquantel (PZQ) - for decades.

127 eneration to show that the isoquinoline drug praziquantel (PZQ) acts as a small molecule neurogenic t

128 overage of community-directed treatment with praziquantel (PZQ) and albendazole (ALB) was analyzed in

129 chistosoma japonicum-infected Filipinos with praziquantel (PZQ) and performed ultrasound to quantify

130 owing the recent development of a paediatric praziquantel (PZQ) formulation for children aged <5 year

131 Praziquantel (PZQ) has been the main drug for controllin

132 m antigen (SWA), or Teg after treatment with praziquantel (PZQ) in a cohort of 187 individuals living

133 osure of worms to the anti-schistosomal drug praziquantel (PZQ) induced significant CaMKII activation

134 Praziquantel (PZQ) is an essential medicine for treating

135 sticercosis with either albendazole (ABZ) or praziquantel (PZQ) is suboptimal.

136 The drug praziquantel (PZQ) is the key clinical therapy for treat

137 Regular treatment with praziquantel (PZQ) is the strategy for human schistosomi

138 The anthelmintic drug praziquantel (PZQ) is used to treat schistosomiasis, a n

139 Mass drug administration with praziquantel (PZQ) monotherapy is considered the mainsta

140 djusted by the concomitant administration of praziquantel (PZQ) showed a 2-fold increase in the propo

141 ould not effectively clear adult worms after praziquantel (PZQ) treatment and suffered increased morb

142 In addition, we evaluate the potential of praziquantel (PZQ) treatment in restoring schistosomiasi

143 iasis develops over time, following repeated praziquantel (PZQ) treatment.

144 nyl derivatives of the antischistosomal drug praziquantel (PZQ) with the formula (eta(6)-PZQ)Cr(CO)3

145 Schistosomiasis is treated with praziquantel (PZQ), an old drug introduced over 40 years

146 l-known drug against schistosomiasis, namely praziquantel (PZQ), are reported.

147 The treatment relies on a single drug, praziquantel (PZQ), making the discovery of new compound

148 on Schistosomes, little is known on whether praziquantel (PZQ), the only licensed drug to treat schi

149 nt drug of choice against schistosomiasis is praziquantel (PZQ), which has minimal side effects and i

150 Schistosomiasis is treated with the drug praziquantel (PZQ), which has proved the therapeutic mai

151 such responses increase after treatment with praziquantel (PZQ).

152 t correlation with the AUC(8) for both total praziquantel (r(2) = 0.81, p < 0.001) and S-praziquantel

153 praziquantel (r(2) = 0.81, p < 0.001) and S-praziquantel (r(2) = 0.84, p < 0.001) than any other sam

154 Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant

155 schistosomiasis is effectively treated with Praziquantel, rapid reinfection with rebound morbidity p

156 The WHO-recommended praziquantel regimen (25 mg/kg three times a day for 2 d

157 re above 90% for several other multiple-dose praziquantel regimens, including 20 mg/kg three times a

158 By the mid-1980s, the effective oral drug, praziquantel, replaced tartar emetic a s treatment f o r

159 programmes on the development and spread of praziquantel resistance is uncertain, but this possibili

160 Despite the limited reports of praziquantel resistance, the relative success of chemoth

161 Praziquantel-resistant worms have been selected for in t

162 rces the need for monitoring the spectrum of praziquantel sensitivity of schistosome populations and

163 Praziquantel showed some effect on fibrosis marker when

164 Praziquantel shows high efficacy against clonorchiasis a

165 on, over a 5-year period at 75% coverage, of praziquantel (single-dose or two-dose regimens) or hypot

166 ndazole) versus standard (annual single-dose praziquantel, six-monthly single-dose albendazole) anthe

167 dicate the inadequacy of current niclosamide-praziquantel strategies alone to achieve sustainable int

168 globin was observed in children who received praziquantel, strongly supporting population-based mass

169 mparisons with previous in vivo studies with praziquantel suggests that these inhibitors outperform t

170 signed in a 1:1:1:1 ratio to receive crushed praziquantel tablets at single standard (40 mg/kg) versu

171 and efficacy of a split dose of 80 mg/kg of praziquantel tablets given in a single day to preschool

172 IC(50)=12.1 muM) and nifedipine, and also by praziquantel, the current drug of choice against schisot

173 istosoma mansoni with reduced sensitivity to praziquantel, the drug currently used to treat this negl

174 Praziquantel, the drug used in public health control pro

175 ch earlier changes in immune reactions after praziquantel therapy in Schistosoma mansoni-infected fis

176 ealth education (WSH) with administration of praziquantel to school-aged children.

177 15 weeks postinfection, one group was given praziquantel to treat schistosomiasis infection.

178 y 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity.

179 ed (1:1) to receive either over-encapsulated praziquantel (total dose 60 mg/kg given as two split dos

180 Praziquantel-treated children had more nausea, abdominal

181 0.96-1.16], pneumonia [1.11, 0.90-1.38]) or praziquantel treatment (malaria [1.00, 0.84-1.20], diarr

182 nes elicited by 3 schistosome to examine how praziquantel treatment alters immune polarization and wh

183 schoolchildren were studied before and after praziquantel treatment and compared to uninfected contro

184 schoolchildren were studied before and after praziquantel treatment and compared with uninfected cont

185 evel, parasites collected after referral for praziquantel treatment are closely related to local pre-

186 Praziquantel treatment for Schistosoma mansoni infection

187 from 92.7% to 95.5% and ERRs >99.5% for all praziquantel treatment groups.

188 Posttreatment results are consistent with praziquantel treatment inducing quantitative and qualita

189 Praziquantel treatment markedly alters polarization of s

190 chistosoma spp and of the number of doses of praziquantel treatment needed to prevent morbidity at di

191 Praziquantel treatment not only cures infection but also

192 chronic S. mansoni infection with or without praziquantel treatment survived malaria, compared to onl

193 at weeks 4-5 (early symptomatic phase), 7-8 (praziquantel treatment), and 13-14 (after treatment).

194 xposed individuals before and after curative praziquantel treatment.

195 and cercaria antigens pre- and 6 weeks post-praziquantel treatment.

196 n in children who received only the baseline praziquantel treatment.

197 Neither albendazole nor praziquantel treatments affected infant response to BCG,

198 and CD23(+) B cells after receiving > or =3 praziquantel treatments over the course of follow-up.

199 munity-wide intensive (quarterly single-dose praziquantel, triple dose albendazole) versus standard (

200 munity-wide intensive (quarterly single-dose praziquantel, triple-dose albendazole) vs standard (annu

201 t population contraction caused by long-term praziquantel use.

202 concurrent administration of albendazole and praziquantel was conducted in>1500 children with high pr

203 uptake of ciprofloxacin, chloramphenicol and praziquantel was conducted.

204 Throughout the whole experiment, praziquantel was present in quantifiable amounts in mush

205 Recognised adverse effects of praziquantel were reported more frequently in the intens

206 r S. mansoni every 4 months and treated with praziquantel when positive (arm A; n=68) or were tested

207 The interaction of praziquantel with SMDR2 may offer new strategies for pot

208 ibraries of target molecules (phenylglycine, praziquantel) with different chemical modifications.